An analysis of 11.3 million screening tests examining the association between recall and cancer detection rates in the English NHS breast cancer screening programme

被引:11
作者
Blanks, R. G. [1 ]
Given-Wilson, R. M. [2 ]
Cohen, S. L. [3 ]
Patnick, J. [1 ]
Alison, R. J. [1 ]
Wallis, M. G. [4 ,5 ]
机构
[1] Univ Oxford, Nuffield Dept Populat Hlth, Canc Epidemiol Unit, Oxford, England
[2] St Georges Univ Hosp Fdn Trust, Dept Radiol, London, England
[3] Publ Hlth England, London, England
[4] Cambridge Univ Hosp NHS Trust, Cambridge Breast Unit, Cambridge, England
[5] Cambridge Univ Hosp NHS Trust, NIHR Cambridge Biomed Res Ctr, Cambridge, England
关键词
Breast neoplasms; Mass screening; Mammography; Recall rate; CARCINOMA IN-SITU; MAMMOGRAPHY; PERFORMANCE; UPDATE; GRADE;
D O I
10.1007/s00330-018-5957-2
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
ObjectiveTo develop methods to model the relationship between cancer detection and recall rates to inform professional standards.MethodsAnnual screening programme information for each of the 80 English NHSBSP units (totalling 11.3 million screening tests) for the seven screening years from 1 April 2009 to 31 March 2016 and some Dutch screening programme information were used to produce linear and non-linear models. The non-linear models estimated the modelled maximum values (MMV) for cancers detected at different grades and estimated how rapidly the MMV was reached (the modelled slope' (MS)). Main outcomes include the detection rate for combined invasive/micro-invasive and high-grade DCIS (IHG) detection rate and the low/intermediate grade DCIS (LIG) detection rate.ResultsAt prevalent screens for IHG cancers, 99% of the MMV was reached at a recall rate of 7.0%. The LIG detection rate had no discernible plateau, increasing linearly at a rate of 0.12 per 1000 for every 1% increase in recall rate. At incident screens, 99% of the MMV for IHG cancer detection was 4.0%. LIG DCIS increased linearly at a rate of 0.18 per 1000 per 1% increase in recall rate.ConclusionsOur models demonstrate the diminishing returns associated with increasing recall rates. The screening programme in England could use the models to set recall rate ranges, and other countries could explore similar methodology.Key Points center dot Question: How can we determine optimum recall rates in breast cancer screening?center dot Findings: In this large observational study, we show that increases in recall rates above defined levels are almost exclusively associated with false positive recalls and a very small increase in low/intermediate grade DCIS.center dot Meaning: High recall rates are not associated with increases in detection of life-threatening cancers. The models developed in this paper can be used to help set recall rate ranges that maximise benefit and minimise harm.
引用
收藏
页码:3812 / 3819
页数:8
相关论文
共 18 条
[1]   Treatment of low-risk ductal carcinoma in situ: is nothing better than something? [J].
Benson, John R. ;
Jatoi, Ismail ;
Toi, Masakazu .
LANCET ONCOLOGY, 2016, 17 (10) :E442-E451
[2]  
Blanks R G, 1996, J Med Screen, V3, P79
[3]   Association between Screening Mammography Recall Rate and Interval Cancers in the UK Breast Cancer Service Screening Program: A Cohort Study [J].
Burnside, Elizabeth S. ;
Vulkan, Daniel ;
Blanks, Roger G. ;
Duffy, Stephen W. .
RADIOLOGY, 2018, 288 (01) :47-54
[4]   Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study [J].
Duffy, Stephen W. ;
Dibden, Amanda ;
Michalopoulos, Dimitrios ;
Offman, Judith ;
Parmar, Dharmishta ;
Jenkins, Jacquie ;
Collins, Beverley ;
Robson, Tony ;
Scorfield, Suzanne ;
Green, Kathryn ;
Hall, Clare ;
Liao, Xiao-Hui ;
Ryan, Michael ;
Johnson, Fiona ;
Stevens, Guy ;
Kearins, Olive ;
Sellars, Sarah ;
Patnick, Julietta .
LANCET ONCOLOGY, 2016, 17 (01) :109-114
[5]   Should breast screening programmes limit their detection of ductal carcinoma in situ? [J].
Evans, AJ ;
Blanks, RG .
CLINICAL RADIOLOGY, 2002, 57 (12) :1086-1089
[6]   An evaluation of breast cancer screening in the South Thames (West) Region of the UKNHS Breast Screening Programme: the first 10 years [J].
Given-Wilson, R ;
Blanks, RG ;
Moss, SM ;
Ansell, J ;
Carter, R ;
Cooke, J ;
Dabon, L ;
Horton, P ;
Kissin, M ;
Rockall, L ;
Rust, A ;
Smee, S ;
Toon, E ;
Vecchi, P .
BREAST, 1999, 8 (02) :66-71
[7]   National Performance Benchmarks for Modern Screening Digital Mammography: Update from the Breast Cancer Surveillance Consortium [J].
Lehman, Constance D. ;
Arao, Robert F. ;
Sprague, Brian L. ;
Lee, Janie M. ;
Buist, Diana S. M. ;
Kerlikowske, Karla ;
Henderson, Louise M. ;
Onega, Tracy ;
Tosteson, Anna N. A. ;
Rauscher, Garth H. ;
Miglioretti, Diana L. .
RADIOLOGY, 2017, 283 (01) :49-58
[8]   The benefits and harms of breast cancer screening: an independent review [J].
Marmot, M. G. ;
Altman, D. G. ;
Cameron, D. A. ;
Dewar, J. A. ;
Thompson, S. G. ;
Wilcox, M. .
BRITISH JOURNAL OF CANCER, 2013, 108 (11) :2205-2240
[9]  
NHS Digital, BREAST SCREEN PROGR
[10]  
Perry N., 2006, EUROPEAN GUIDELINES